Search clinical trials for: NY-ESO-1(157-165) Peptide-pulsed Autologous Dendritic Cell Vaccine

Total 72 results

Maria Sklodowska-Curie National Research Institute...

Unknown

Melanoma Vaccine in Treating Patients With Stage III Melanoma After Surgery to Remove Lymph Nodes

Melanoma (Skin)

Poland
Ludwig Institute for Cancer Research
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Malignant Glioma

Brain and Central Nervous System Tumors

United States
Universidad Nacional de Colombia
Fundación Salud de los Andes

Not yet recruiting

Personalized Vaccine for TNBC Immunotherapy (TEBICA003 TNBC)

Breast Cancer Female

Colombia
Jan Walewski

Completed

Dendritic Cell Vaccine in Treating Patients With Indolent B-Cell Lymphoma or Multiple Myeloma

Lymphoma | Multiple Myeloma and Plasma Cell Neoplasm

Poland
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)

Completed

Dendritic Cell Vaccination During Lymphoid Reconstruction

Intraocular Melanoma | Melanoma (Skin)

United States
The Republican Research and Practical Center for...
Belarusian State Medical University

Completed

Dendritic Cell Immunotherapy for the Patients With Pancreatic Cancer

Pancreatic Neoplasms | Dendritic Cells

Belarus
Baylor College of Medicine
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Metastatic, Progressive Prostate Cancer

Prostate Cancer

United States
Leo W. Jenkins Cancer Center
H. Lee Moffitt Cancer Center and Research Institute

Terminated

Direct Tumor Injection KLH-Pulsed Dendritic Cells in Unresectable Pancreatic Cancer

Metastatic Pancreatic Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb; National Cancer Institute (NCI); Medarex

Completed

Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma

Melanoma (Skin)

United States
Statens Serum Institut
Rigshospitalet, Denmark; Hvidovre University Hospital

Completed

Vaccination With Autologous Dendritic Cells Pulsed With HIV-Antigens for Treatment of Patients With Chronic HIV-Infection (HIVDCVac)

HIV Infections

Denmark
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

Lung Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)

Completed

Adenovirus CCL-21 Transduced MART-1/gp100/Tyrosinase/NY-ESO-1 Peptide-Pulsed Dendritic Cells Matured

Melanoma (Skin)

United States
Robert Ferris
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Head and Neck Cancer

Head and Neck Cancer

United States
University of Southern California
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Intraocular Melanoma | Melanoma (Skin)

United States
Centre Hospitalier Universitaire Vaudois
Immutep S.A.S.

Terminated

Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma Patients (LAG-3/IMP321)

Melanoma

Switzerland
Jonsson Comprehensive Cancer Center
National Institutes of Health (NIH)

Completed

Vaccine Therapy in Treating Patients With Stage IV or Recurrent Malignant Melanoma

Melanoma (Skin)

United States
Jonsson Comprehensive Cancer Center

Completed

Vaccine for Patients With Newly Diagnosed or Recurrent Low-Grade Glioma

Adult Diffuse Astrocytoma | Adult Mixed Glioma | Adult Oligodendroglioma | Recurrent Adult Brain Tumor | Adult Oligoastrocytoma

United States
Jonsson Comprehensive Cancer Center

Completed

Vaccine Therapy in Treating Patients With Stage IV or Relapsed Malignant Melanoma

Melanoma

United States
Columbia University
National Cancer Institute (NCI)

Terminated

Vaccine Therapy and Sargramostim in Treating Patients With Soft Tissue Sarcoma

Sarcoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Recurrent Glioblastoma

Recurrent Glioblastoma | Giant Cell Glioblastoma | Recurrent Gliosarcoma

United States
Jonsson Comprehensive Cancer Center
Bristol-Myers Squibb; National Cancer Institute (NCI); Eunice Kennedy Shriver... and other collaborators

Completed

Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1 (NYM)

Childhood Solid Neoplasm | Metastatic Neoplasm | Adult Solid Neoplasm

United States
H. Lee Moffitt Cancer Center and Research Institute
Johns Hopkins All Children's Hospital

Withdrawn

A Combined Cell Therapy Approach to the Treatment of Neuroblastoma

Neoplasms, Nerve Tissue | Neuroblastoma
Herbert Irving Comprehensive Cancer Center
National Cancer Institute (NCI)

Unknown

Vaccine Therapy With or Without Sargramostim in Treating Patients With High-Risk or Metastatic Melanoma

Melanoma (Skin)

United States
University of Sao Paulo General Hospital

Not yet recruiting

Therapeutic Vaccine Based on aDC1 Dendritic Cells for the Control of Viremia After ATI in HIV Infected Individuals

HIV Vaccine

Brazil
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Stage IV Melanoma

Melanoma (Skin)

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Refractory Metastatic Melanoma

Melanoma (Skin)

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Withdrawn

A Cytomegalovirus-Directed Vaccine (CMV-alphaDC1) for Preventing Cytomegalovirus Infection or Reactivation in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Hematopoietic and Lymphoid System Neoplasm | Cytomegaloviral Infection

United States
Georgetown University
United States Department of Defense

Suspended

A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients

Ovarian Cancer Stage IV | Ovarian Cancer Stage III | Ovarian Cancer Stage 3

United States
PrimeVax Immuno-Oncology Inc.
Walter Reed Army Institute of Research (WRAIR)

Not yet recruiting

Intratumoral Injection of PV-001-DV Plus DC in Patients With Melanoma

Advanced Melanoma
Centre Hospitalier Universitaire Vaudois

Recruiting

Personalized Vaccine With SOC Chemo Followed by Nivo in Pancreatic Cancer

Pancreatic Adenocarcinoma

Switzerland
Catherine Anne Chappell
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Completed

Treatment of Chronic Hepatitis C During Pregnancy With Sofosbuvir/Velpatasvir

Hepatitis C, Chronic

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy and Biological Therapy in Treating Patients With Advanced Cancer

Cervical Cancer | Breast Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Lung Cancer

United States
University of Pennsylvania
Parker Institute for Cancer Immunotherapy; Tmunity Therapeutics

Terminated

NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)

Melanoma | Multiple Myeloma | Myxoid/Round Cell Liposarcoma | Synovial Sarcoma

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI); University of Southern California; University... and other collaborators

Completed

Study of Gene Modified Immune Cells in Patients With Advanced Melanoma (F5)

Metastatic Melanoma

United States
Centre Hospitalier Universitaire Vaudois

Recruiting

Personalized DC Vaccines in Non Small Cell Lung Cancer

Non-small Cell Lung Cancer

Switzerland
National Cancer Institute (NCI)

Terminated

Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer

Metastatic Cancer | Metastatic Melanoma | Metastatic Renal Cell Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb; National Cancer Institute (NCI); Medarex

Completed

Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558

Melanoma (Skin)

United States
Jonsson Comprehensive Cancer Center

Active, not recruiting

Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies

Malignant Neoplasm

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Terminated

Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies

Unspecified Adult Solid Tumor, Protocol Specific

United States
Beijing Tiantan Hospital
ZhongSheng BioTech Inc.

Active, not recruiting

Safety & Efficacy of DC Vaccine and TMZ for the Treatment of Newly-diagnosed Glioblastoma After Surgery

Glioblastoma Multiforme of Brain

China
Mustafa Khasraw, MBChB, MD, FRCP, FRACP

Completed

DC Migration Study for Newly-Diagnosed GBM (ELEVATE)

Glioblastoma | Glioblastoma Multiforme | Giant Cell Glioblastoma | Astrocytoma, Grade IV

United States
National Cancer Institute (NCI)

Terminated

p53 Vaccine for Ovarian Cancer

Ovarian Neoplasm

United States
National Cancer Institute (NCI)

Terminated

Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients

Melanoma

United States
Joseph Baar, MD, PhD

Completed

Type I-Polarized Autologous Dendritic Cell Vaccine With Tumor Blood Vessel Antigen-Derived Peptides in Metastatic Breast Cancer Patients

Breast Cancer | Metastatic Breast Cancer

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Interferon-gamma or Aldesleukin and Vaccine Therapy in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm
Roswell Park Cancer Institute
Eisai Inc.

Completed

Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Recurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity Cancer | Recurrent Fallopian Tube Cancer

United States
National Cancer Institute (NCI)

Completed

Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, Peptide Vaccine Plus Montanide ISA-51, and Interleukin-2 in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
M.D. Anderson Cancer Center

Completed

Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent Sarcoma

Recurrent Synovial Sarcoma | HLA-A*0201 Positive Cells Present | NY-ESO-1 Positive Tumor Cells Present | Recurrent Myxoid Liposarcoma

United States
Jonsson Comprehensive Cancer Center
Bristol-Myers Squibb; Northwest Biotherapeutics; Brain Tumor Funders Collaborative

Withdrawn

Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma

Gliosarcoma | Recurrent Glioblastoma | Oligodendroglioma | Small Cell Glioblastoma | Giant Cell Glioblastoma

United States

Search clinical trials for: NY-ESO-1(157-165) Peptide-pulsed Autologous Dendritic Cell Vaccine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Equatorial Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations